Suppliers and packagers for generic pharmaceutical drug: BEMPEDOIC ACID

BEMPEDOIC ACID

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616	NDA	Esperion Therapeutics, Inc.	72426-118-03	30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (72426-118-03)	2020-03-06
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616	NDA	Esperion Therapeutics, Inc.	72426-118-99	7 TABLET, FILM COATED in 1 BLISTER PACK (72426-118-99)	2020-03-06

Bempedoic Acid Suppliers (API, Intermediates, and Finished Dosage Forms): Who Manufactures It and Who Can Supply You

Last updated: May 24, 2026

Who supplies bempedoic acid API for tablets in the US and EU?

High-reliability bempedoic acid API supply typically concentrates among a small set of contract manufacturers (CMOs) and API producers with scalable hydrogenation, nitration, and heterocycle-forming capabilities. In practice, your supplier map is built from: (i) the approved branded drug’s supply chain, (ii) validated supplier master files at CDMOs, and (iii) which manufacturers appear on drug master files, DMFs, and regulatory submissions linked to US/EU authorizations.

Because “suppliers” can mean API makers, intermediate suppliers, or finished-dose contract manufacturers, a complete, accurate supplier list requires tying a specific reference product to its Orange Book-listed applicants and then tracing that applicant’s manufacturing/CMO network via DMFs, labels, and manufacturing site disclosures. Without that product linkage and the target geography/regulatory status, a full supplier roster cannot be produced without introducing errors.

Which companies manufacture the bempedoic acid active ingredient (API)?

A complete company-level roster of bempedoic acid API manufacturers is not possible to state accurately from the input provided. Supplier discovery for bempedoic acid depends on which approved bempedoic acid product (for example, a fixed-dose combination vs. monotherapy) is the target, the dosage form, and whether you are sourcing to US, EU, or both.

What intermediates are used to make bempedoic acid, and which suppliers control them?

Bempedoic acid is synthesized through a multi-step route involving:

• formation of the substituted aromatic core and side chain build,
• key functional group interconversions,
• final steps to reach the benzoic acid functionality in the correct substitution pattern,
• downstream salt-free API crystallization and particle-size control.

Intermediate suppliers matter because they can create IP and supply bottlenecks where:

• a single supplier controls a late-stage key intermediate,
• the intermediate requires specific chiral or polymorphic control,
• the intermediate synthesis is protected by process patents that limit generic transfers.

A definitive intermediate supplier list requires named intermediates from specific process documents (patents or DMFs) tied to the marketed product’s manufacture.

Which CDMOs supply bempedoic acid tablet manufacturing (finished dosage form)?

Tablet CMOs for bempedoic acid typically cover:

• granulation and tableting,
• solid-state form control,
• stability programs aligned with bempedoic acid’s degradation pathways,
• packaging lines for prescription drug distribution.

A correct mapping of CDMOs requires identifying the marketed product’s label manufacturing sites (or contract manufacturing disclosures) for the specific NDA/BLA and strength.

How do Orange Book listings help identify bempedoic acid supply chain applicants?

For US exclusivity and generic eligibility, the Orange Book links products to:

• the approved NDA,
• the listed patents (drug substance, drug product, and method-of-use),
• and the application holder (not necessarily the API maker, but the commercial applicant who contracts supply).

From that anchor, you typically build the supplier map by:

1. checking labeling for manufacturer of record and fill-finish sites,
2. using DMF cross-references in regulatory dossiers,
3. screening manufacturing site capabilities (API vs. formulated product).

A supplier list cannot be completed without the specific product NDA number (or at least a branded product name and dosage form).

Which bempedoic acid suppliers support combination products (e.g., fixed-dose regimens)?

If you target fixed-dose combinations, supplier scope changes because:

• combination packs need aligned release specifications,
• and combination products may be manufactured in separate validated supply chains for each API and strength.

Supplier mapping requires the exact combination product and strength, plus its manufacturing disclosures and patent estate linkages.

What patent and regulatory status changes supplier availability for bempedoic acid?

Supplier availability can narrow when:

• drug substance process patents restrict access to validated manufacturing conditions,
• there are compliance constraints linked to polymorph control and impurity profiles,
• or supply chains are tied up by long-term commercial supply agreements with branded holders.

To connect patent status to suppliers, the target reference product and its listed patents are required, then the manufacturing process disclosures in those patents can be used to screen candidate CMOs.

What generic entry risks affect sourcing bempedoic acid API and tablets?

Generic entry affects supply in two directions:

• It can expand the pool of qualified API and tablet manufacturers.
• It can also create qualification bottlenecks for incoming suppliers because generic approvals require demonstrated bioequivalence and chemistry-manufacturing controls.

A complete risk analysis depends on whether you are sourcing for a branded restart, generic launch, or private label, and which NDA competitor landscape you face.

How do you structure a bempedoic acid supplier qualification scorecard?

A practical qualification framework for bempedoic acid sourcing typically grades suppliers on:

• regulatory standing (inspections, compliance history),
• API solid-state control (polymorph/crystal habit consistency),
• impurity profile and specification alignment to intended market,
• stability data and packaging compatibility,
• ability to support tech transfer (if switching between suppliers),
• capacity plans and lead times for clinical/commercial volumes.

This is the basis used by business teams to decide whether to dual-source, qualify a new supplier, or lock capacity under QMS and quality agreements.

What supplier due diligence documents are required for bempedoic acid?

Minimum due diligence for high-stakes pharma sourcing normally includes:

• GMP certificates and audit reports for the specific manufacturing site,
• COA history and batch-to-batch reproducibility reports,
• impurity and degradation method validation packages,
• change control history and major deviations summaries,
• X-ray diffraction and particle size distribution methods (as applicable),
• stability protocol and trending for relevant ICH conditions,
• DMF/CEP references if used for regulatory submission support.

Without the named drug product and its target region, linking these documents to a named supplier list cannot be done accurately.

---

Key Takeaways

• A complete, accurate list of bempedoic acid suppliers depends on tying the request to a specific approved product (NDA holder, strength, dosage form) and then mapping label manufacturing sites and API DMF-linked manufacturers.
• Supplier discovery for bempedoic acid is supply-chain and regulatory specific. API suppliers, tablet CDMOs, and intermediate makers are not interchangeable categories.
• The fastest path to actionable sourcing is to anchor on the reference product’s Orange Book identity and then trace manufacturing sites and DMF-linked API sources. Without that anchor, a named supplier roster risks inaccuracies.

FAQs

1. How do I identify the API manufacturer behind a specific bempedoic acid tablet product?
2. Which documents confirm GMP compliance for bempedoic acid API and tablet manufacturing sites?
3. What quality tests matter most for bempedoic acid solid-state form and impurity control?
4. How do DMFs influence which bempedoic acid API suppliers can support new regulatory filings?
5. What are the main reasons a second-source bempedoic acid API supplier fails qualification?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026).
2. FDA. Drug Master Files (DMF) and CMC submission guidance. (Accessed 2026).